Thiabendazole is a benzimidazole used in the treatment of strongyloides, cutaneous larva migrans, visceral larva migrans, and trichinosis infections. 2-Substituted benzimidazole first introduced in 1962.
- Mechanism
- Curator reviewed
The precise mode of action of thiabendazole on the parasite is unknown, but it most likely inhibits the helminth-specific enzyme fumarate reductase.
- Primary indication
- For the treatment of strongyloidiasis (threadworm), cutaneous larva migrans (creeping eruption), visceral larva migrans, and trichinosis.Curator reviewed
- Formula / weight
- C10H7N3S · 201.248 g/mol (avg)
- First approval
- Canada, 1969 · United States, 1967
- Also known as
- TBDZ · Tiabendazole
- Code names
- MK-360 · NSC-525040 · NSC-90507
Resolves to
Clinical / RWD
Structure
InChIKey
WJCNZQLZVWNLKY-UHFFFAOYSA-NSMILESN1C2=CC=CC=C2N=C1C1=CSC=N1Targets
What you can answer from here — as of September 12, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Thiabendazole, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account